Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Essilor Of America, Inc.

Approvalsnovel device granted (FDA De Novo)25 Sept 2025

Essilor Of America, Inc.

25 Sept 2025: Novel device granted (FDA De Novo) · Essilor® Stellest®. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
25 Sept 2025
Device
Essilor® Stellest®
Specialty
Ophthalmic
Product Code
QUR
Country
United States
Location
Dallas, TX
Submitted
2025-04-28
Reference
DEN250016
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Essilor Of America, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.